CoChat

Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD

Open access
Polyzos, Stergios A, Perakakis, Nikolaos, Boutari, Chrysoula, Kountouras, Jannis, Ghaly, Wael, Anastasilakis, Athanasios D, Karagiannis, Asterios, Mantzoros, Christos S · 2020 · The Journal of Clinical Endocrinology & Metabolism
Cited by 46

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Aims: To investigate circulating levels and liver gene expression of 3 hormonal pathways associated with obesity, insulin resistance, and inflammation to identify leads towards potential diagnostic markers and therapeutic targets in patients with nonalcoholic fatty liver disease (NAFLD). Methods: We compared circulating levels of (1) proglucagon-derived hormones (glucagon-like peptide [GLP]-1, GLP-2, glicentin, oxyntomodulin, glucagon, major proglucagon fragment [MPGF]), (2) follistatins-activins (follistatin-like [FSTL]3, activin B), (3) IGF axis (insulin-like growth factor [IGF]-1, total and intact IGF binding protein [IGFBP]-3 and IGFBP-4, and pregnancy-associated plasma protein [PAPP]-A) in 2 studies: (1) 18 individuals with early stage NAFLD versus 14 controls (study 1; early NAFLD study) and in (2) 31 individuals with biopsy proven NAFLD (15 with simple steatosis [SS] and 16 with nonalcoholic steatohepatitis [NASH]), vs 50 controls (24 lean and 26 obese) (study 2). Liver gene expression was assessed in 22 subjects (12 controls, 5 NASH, 5 NASH-related cirrhosis). Results: Patients in early stages of NAFLD demonstrate higher fasting MPGF and lower incremental increase of glicentin during oral glucose tolerance test than controls. In more advanced stages, FSTL3 levels are higher in NASH than simple steatosis and, within NAFLD patients, in those with more severe lobular and portal inflammation. The IGF-1/intact IGFBP-3 ratio is lower in patients with liver fibrosis. Genes encoding follistatin, activin A, activin B, and the IGF-1 receptor are higher in NASH. Conclusion: MPGF and glicentin may be involved in early stages of NAFLD, whereas FSTL3 and IGF-1/intact IGFBP3 in the progression to NASH and liver fibrosis respectively, suggesting potential as diagnostic markers or therapeutic targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgz172

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 36

  1. Polyzos, 2016, Nonalcoholic fatty future disease, Metabolism., 65, 1007, 10.1016/j.metabol.2015.12.009 · DOI
  2. Polyzos, 2016, Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: a systematic review, Metabolism., 65, 1297, 10.1016/j.metabol.2016.05.013 · DOI
  3. Stefan, 2019, Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies, Lancet Diabetes Endocrinol., 7, 313, 10.1016/S2213-8587(18)30154-2 · DOI · Paper page
  4. Boutari, 2018, Association of adipokines with development and progression of nonalcoholic fatty liver disease, Endocrinol Metab (Seoul)., 33, 33, 10.3803/EnM.2018.33.1.33 · DOI · Paper page
  5. Holst, 2016, Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor, Surg Obes Relat Dis., 12, 1236, 10.1016/j.soard.2016.02.033 · DOI · Paper page
  6. Feng, 2017, Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease, J Diabetes., 9, 800, 10.1111/1753-0407.12555 · DOI · Paper page
  7. Petit, 2017, Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the Lira-NAFLD Study, J Clin Endocrinol Metab., 102, 407
  8. Hedger, 2013, The activins and their binding protein, follistatin—diagnostic and therapeutic targets in inflammatory disease and fibrosis, Cytokine Growth Factor Rev., 24, 285, 10.1016/j.cytogfr.2013.03.003 · DOI
  9. Anastasilakis, 2016, Circulating follistatin displays a day-night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans, Metabolism., 65, 1459, 10.1016/j.metabol.2016.07.002 · DOI
  10. Moragianni, 2011, Short-term energy deprivation alters activin a and follistatin but not inhibin B levels of lean healthy women in a leptin-independent manner, J Clin Endocrinol Metab., 96, 3750, 10.1210/jc.2011-1453 · DOI
  11. Vamvini, 2011, Energy deprivation alters in a leptin- and cortisol-independent manner circulating levels of activin A and follistatin but not myostatin in healthy males, J Clin Endocrinol Metab., 96, 3416, 10.1210/jc.2011-1665 · DOI · Paper page
  12. Brandt, 2015, Over-expression of Follistatin-like 3 attenuates fat accumulation and improves insulin sensitivity in mice, Metabolism., 64, 283, 10.1016/j.metabol.2014.10.007 · DOI
  13. Brandt, 2014, Obesity and low-grade inflammation increase plasma follistatin-like 3 in humans, Mediators Inflamm., 2014, 364209, 10.1155/2014/364209 · DOI
  14. de Kretser, 2012, The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair, Mol Cell Endocrinol., 359, 101, 10.1016/j.mce.2011.10.009 · DOI · Paper page
  15. Perakakis, 2019, Follistatins in glucose regulation in healthy and obese individuals, Diabetes Obes Metab., 21, 683, 10.1111/dom.13572 · DOI · Paper page
  16. Polyzos, 2016, Activin A and follistatin in patients with nonalcoholic fatty liver disease, Metabolism., 65, 1550, 10.1016/j.metabol.2016.07.009 · DOI · Paper page
  17. Dichtel, 2017, The association between IGF-1 levels and the histologic severity of nonalcoholic fatty liver disease, Clin Transl Gastroenterol., 8, e217, 10.1038/ctg.2016.72 · DOI · Paper page
  18. García-Galiano, 2007, IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients, Obes Surg., 17, 493, 10.1007/s11695-007-9087-1 · DOI
  19. Sumida, 2015, Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease, Hepatol Res., 45, 771, 10.1111/hepr.12408 · DOI · Paper page
  20. Miller, 2014, Serum proteome of nonalcoholic fatty liver disease: a multimodal approach to discovery of biomarkers of nonalcoholic steatohepatitis, J Gastroenterol Hepatol., 29, 1839, 10.1111/jgh.12614 · DOI
  21. Völzke, 2009, Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample, Eur J Endocrinol., 161, 705, 10.1530/EJE-09-0374 · DOI · Paper page
  22. Hjortebjerg, 2018, IGFBP-4 and PAPP-A in normal physiology and disease, Growth Horm IGF Res., 41, 7, 10.1016/j.ghir.2018.05.002 · DOI
  23. Polyzos, 2013, Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index, Ann Hepatol., 12, 749, 10.1016/S1665-2681(19)31316-X · DOI
  24. Bedogni, 2006, The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population, BMC Gastroenterol., 6, 33, 10.1186/1471-230X-6-33 · DOI · Paper page
  25. Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology., 41, 1313, 10.1002/hep.20701 · DOI · Paper page
  26. Perakakis, Supplemental material related to the article entitled “Targeted analysis of three hormonal systems identifies molecules associated with the presence and severity of NAFLD.” figshare. Journal contribution. 2019
  27. Brunt, 1999, Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions, Am J Gastroenterol., 94, 2467, 10.1111/j.1572-0241.1999.01377.x · DOI · Paper page
  28. Tuccinardi, 2019, Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: a six-month, randomized, placebo-controlled, double-blind clinical trial, Diabetes Obes Metab., 21, 1487, 10.1111/dom.13655 · DOI · Paper page
  29. Bernsmeier, 2014, Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease, Plos One., 9, e87488, 10.1371/journal.pone.0087488 · DOI · Paper page
  30. Raffort, 2017, Insights on glicentin, a promising peptide of the proglucagon family, Biochem Med (Zagreb)., 27, 308, 10.11613/BM.2017.034 · DOI · Paper page
  31. Mukherjee, 2007, FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults, Proc Natl Acad Sci U S A., 104, 1348, 10.1073/pnas.0607966104 · DOI · Paper page
  32. Ungerleider, 2013, Increased activin bioavailability enhances hepatic insulin sensitivity while inducing hepatic steatosis in male mice, Endocrinology., 154, 2025, 10.1210/en.2012-1844 · DOI
  33. Liu, 2015, Association of follistatin-like 3 concentrations in serum and synovial fluid with the radiographic severity of knee osteoarthritis, Int J Clin Exp Med., 8, 18884
  34. Kucera, 2015, Reference values of IGF1, IGFBP3 and IGF1/IGFBP3 ratio in adult population in the Czech Republic, Clin Chim Acta., 444, 271, 10.1016/j.cca.2015.02.036 · DOI
  35. Bach, 2005, IGF-binding proteins–the pieces are falling into place, Trends Endocrinol Metab., 16, 228, 10.1016/j.tem.2005.05.005 · DOI · Paper page
  36. Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem., 18, 499, 10.1093/clinchem/18.6.499 · DOI · Paper page

Cited by

See all 46

Metadata

Authors
Polyzos, S. A., Perakakis, N., Boutari, C., Kountouras, J., Ghaly, W., Anastasilakis, A. D., Karagiannis, A., & Mantzoros, C. S.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2019-11-06
Volume
105
Issue
3
Pages
e390-e400
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2989029869
Cited by
46
References
10
FWCI
3.31
Type
journal article
Language
en
Open access
green
Funders
National Institutes of Health (K24DK081913)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. https://app.cochat.ai/papers/10.1210/clinem/dgz172
The paper
Polyzos, S. A., Perakakis, N., Boutari, C., Kountouras, J., Ghaly, W., Anastasilakis, A. D., Karagiannis, A., & Mantzoros, C. S. (2020). Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgz172

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.